- Home
- BMEA vs EDAP Comparison
BMEA vs EDAP Comparison
Compare BMEA & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- EDAP
- Stock Information
- Founded
- BMEA 2017
- EDAP 1979
- Country
- BMEA United States
- EDAP France
- Employees
- BMEA N/A
- EDAP N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BMEA Health Care
- EDAP Health Care
- Exchange
- BMEA Nasdaq
- EDAP Nasdaq
- Market Cap
- BMEA 65.8M
- EDAP 53.8M
- IPO Year
- BMEA 2021
- EDAP 1997
- Fundamental
- Price
- BMEA $1.44
- EDAP $1.78
- Analyst Decision
- BMEA Strong Buy
- EDAP Buy
- Analyst Count
- BMEA 11
- EDAP 3
- Target Price
- BMEA $27.60
- EDAP $8.50
- AVG Volume (30 Days)
- BMEA 703.1K
- EDAP 59.7K
- Earning Date
- BMEA 05-05-2025
- EDAP 05-15-2025
- Dividend Yield
- BMEA N/A
- EDAP N/A
- EPS Growth
- BMEA N/A
- EDAP N/A
- EPS
- BMEA N/A
- EDAP N/A
- Revenue
- BMEA N/A
- EDAP $67,840,467.00
- Revenue This Year
- BMEA N/A
- EDAP $0.74
- Revenue Next Year
- BMEA N/A
- EDAP $0.37
- P/E Ratio
- BMEA N/A
- EDAP N/A
- Revenue Growth
- BMEA N/A
- EDAP 3.69
- 52 Week Low
- BMEA $1.29
- EDAP $1.26
- 52 Week High
- BMEA $13.07
- EDAP $6.01
- Technical
- Relative Strength Index (RSI)
- BMEA 39.69
- EDAP 43.45
- Support Level
- BMEA $1.29
- EDAP $1.59
- Resistance Level
- BMEA $1.52
- EDAP $1.89
- Average True Range (ATR)
- BMEA 0.14
- EDAP 0.16
- MACD
- BMEA 0.01
- EDAP -0.03
- Stochastic Oscillator
- BMEA 28.17
- EDAP 27.94
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.